Atara reports growing losses, but plenty of cash left
Atara Biotherapeutics continued seeing losses in the third quarter of fiscal year 2021, but has enough cash on hand to remain solvent as it awaits news on its tab-cel therapy treatment in early 2022. Atara, a South San Francisco-based immunotherapy based company with major operations in Westlake Village, reported net losses of $84.7 million in Read More →
Amgen reports revenue growth in Q3 but lowers full-year guidance
Sales increases across Amgen’s drug lineup drove increases in revenue and non-GAAP earnings at the Thousand Oaks biotech company during the third quarter, according to its Nov. 2 earnings release, but pandemic issues persist, and the company lowered its revenue guidance for the year. Amgen, one of the largest biotech companies in the world, reported Read More →
CEO of St. John’s hospitals in Oxnard and Camarillo resigns
The CEO of the two Dignity Health hospitals in Ventura County, Darren Lee, has resigned, Dignity Health announced Oct. 28. Lee was the top executive at of St. John’s Regional Medical Center in Oxnard and St. John’s Hospital Camarillo. In a statement announcing his departure, a hospital spokesperson said on Oct. 28 that he had Read More →
MannKind shares drop 18% after FDA says it will pass on new blood pressure drug
Shares of Westlake Village-based MannKind Corp. dropped 18% on Oct. 18, after the U.S. Food and Drug Administration did not approve a hypertension treatment the company is developing with United Therapeutics. In a complete letter response, the FDA declined to approve a new drug application for Tyvasio DPI, a treatment being developed by MannKind and Read More →
Amgen’s investment in Neumora marks a return to neuroscience research
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen goes full speed ahead on biosimilar drugs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Sansum Institute kept its diabetes research going in a year like no other
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
